With a drug-treated population of about 2.5 million people in the United States and EU5, the moderate to severe psoriasis market has been a lucrative space for drug developers, resulting in a plethora of approved agents with diverse mechanisms of action to treat the disease. In recent years, the dynamics of the psoriasis market have started to change; there has been a shift from the use of established TNF-α inhibitors as earlier-line agents to the earlier use of other biologics like the IL-12/23 inhibitor Stelara, IL-17 inhibitors such as Cosentyx and Taltz, and IL-23 inhibitors such as Tremfya and Skyrizi. Nonetheless, the early- and late-phase pipeline for moderate to severe psoriasis has several promising agents because drug developers realize that, despite multiple current treatments, novel agents are needed that can differentiate themselves on the attributes of efficacy, convenient delivery, and ability to treat a broad patient population.
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 31 European dermatologists fielded in December 2020
Key companies: AbbVie, Janssen, Amgen, Novartis, Eli Lilly, UCB
Key drugs: Humira, Stelara, Otezla, Cosentyx, Taltz, Tremfya, Skyrizi